LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004.

LISOCABTAGENE MARALEUCEL (LISO-CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004 B Introduction: b Achieving durable CR with current treatment is uncommon in patients (pts) with R/R CLL/SLL that progressed on BTKi and failed venetoclax (ven)-based treatment. Keyword: cellular therapies B Conflicts of interests pertinent to the abstract b B T. Siddiqi b Consultant or advisory role: Astra Zeneca, BMS, Celgene, Kite pharma, Beigene, Abbvie Research funding: Astra Zeneca, BMS, Celgene, Oncternal, Ascentage pharma, Kite pharma, TG therapeutics, Pharmacyclics, Juno therapeutics Other remuneration: Speaker's Bureau: Astra Zeneca, BMS, Beigene B D. G. Maloney b Consultant or advisory role: A2 Biotherapeutics, Member of the Scientific Advisory Board GRAPH Navan Technologies, Member of the Scientific Advisory Board GRAPH Chimeric Therapeutics, Member of the Scientific Advisory Board GRAPH Genentech, Member and Chair of the Lymphoma Steering Committee GRAPH BMS, Member of the JCAR017 EAP-001 Safety Review Committee GRAPH BMS, Member, CLL Strategic Council GRAPH ImmPACT Bio, Member, Clinical Advisory Board, CD19/CD20 bi-specific CAR-T Cell Therapy Program GRAPH Gilead Sciences, Member, Scientific Review Committee, Research Scholars Program in Hematologic Malignancies GRAPH Interius. [Extracted from the article]